Shares of Claris Lifesciences surged 20 per cent amid reports that big national and international companies are in the fray to buy company's injectible business.
The stock zoomed 19.96 per cent to Rs 248.20 -- its upper circuit limit on the BSE.
The company's market capitalisation went up by Rs 454.96 crore to Rs 1,583.96 crore.
On the volume front, 7.96 lakh shares of the company changed hands at the BSE during the day.
Meanwhile, in a clarification to the BSE, the company said, "We state that at present we are not negotiating the sale of stake in the injectables business, and the Board of Directors of the company has neither considered nor taken any decision in this regard."
For the growth of the business, company continues to explore and evaluate inorganic and strategic opportunities in various forms from time to time, however nothing definitive in this regard has happened, it said.
We will duly notify the exchanges upon the occurrence of any definitive developments in this regard, the company added.
